Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23425607 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds
Conditions: Rubella Disease;   Mumps Disease;   Varicella Disease;   Measles Disease
Interventions: Biological: Priorix-Tetra TM (combined measles-mumps-rubella-varicella vaccine);   Biological: GSK Biologicals' 208136, new formulation

Indicates status has not been verified in more than two years